Figure 2.
Clinical course of the patient from the admission day to the discharge
day (day 113). Lymphocyte follows left axis and LDH follows right axis.
After debulking by CPA+PSL+Rituximab, venetoclax was started, and the
dose was increased gradually; the treatment response was good. Because
of the complications of CRBSI, venetoclax treatment was stopped. After
the exchange of the catheter and antibiotic therapy, venetoclax was
restarted safely.
*Ven: venetoclax, CPA: cyclophosphamide, CRBSI: catheter-related
bloodstream infection, PSL: prednisolone, R: rituximab.